EMAIL THIS PAGE TO A FRIEND

Journal of Parkinson's disease

Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease.


PMID 24927756

Abstract

Parkinson's disease (PD) is a progressive, multi-focal neurodegenerative disease for which there is no effective disease modifying treatment. A critical requirement for designing successful clinical trials is the development of robust and reproducible biomarkers identifying PD in preclinical stages. To investigate the potential for a cluster of biomarkers visualized with multiple analytical platforms to provide a clinically useful tool. Gas Chromatography-Mass Spectrometry (GC-TOFMS) based metabolomics and immunoassay-based protein/peptide analyses on samples from patients with PD diagnosed in Northern Sweden. Low molecular weight compounds from both plasma and cerebrospinal fluid (CSF) from 20 healthy subjects (controls) and 20 PD patients at the time of diagnosis (baseline) were analyzed. In plasma, we found a significant increase in several amino acids and a decrease in C16-C18 saturated and unsaturated fatty acids in patients as compared to control subjects. We also observed an increase in plasma levels of pyroglutamate and 2-oxoisocaproate (ketoleucine) that may be indicative of increased metabolic stress in patients. In CSF, there was a generally lower level of metabolites in PD as compared to controls, with a specific decrease in 3-hydroxyisovaleric acid, tryptophan and creatinine. Multivariate analysis and modeling of metabolites indicates that while the PD samples can be separated from control samples, the list of detected compounds will need to be expanded in order to define a robust predictive model. CSF biomarker immunoassays of candidate peptide/protein biomarkers revealed a significant decrease in the levels of Aβ-38 and Aβ-42, and an increase in soluble APPα in CSF of patients. Furthermore, these peptides showed significant correlations to each other, and positive correlations to the CSF levels of several 5- and 6-carbon sugars. However, combining these metabolites and proteins/peptides into a single model did not significantly improve the statistical analysis. Together, this metabolomics study has detected significant alterations in plasma and CSF levels of a cluster of amino acids, fatty acids and sugars based on clinical diagnosis and levels of known protein and peptide biomarkers.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

45840
Acetic anhydride
C4H6O3
92360
Chlorotrimethylsilane, puriss., ≥99.0% (GC)
C3H9ClSi
89595
Chlorotrimethylsilane, for GC derivatization, ≥99.0% (GC)
C3H9ClSi
G0355000
Glutamic acid, European Pharmacopoeia (EP) Reference Standard
C5H9NO4
M3128
Myristic acid, Sigma Grade, ≥99%
C14H28O2
70079
Myristic acid, analytical standard
C14H28O2
70082
Myristic acid, ≥98.0% (GC)
C14H28O2
W276405
Myristic acid, ≥95%, FCC, FG
C14H28O2
W276413
Myristic acid, natural, ≥98.5%, FG
C14H28O2
130087
Myristic acid, 95%
C14H28O2
PHR1124
Myristic acid, Pharmaceutical Secondary Standard; Certified Reference Material
C14H28O2
M0789
N-Methyl-bis(trifluoroacetamide), for GC derivatization, ≥97.0% (GC)
C5H3F6NO2
65943
N-Methyl-bis(trifluoroacetamide), for GC derivatization, ≥99.0% (GC)
C5H3F6NO2
43051
Palmitic acid, certified reference material, TraceCERT®
C16H32O2
1492007
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
C16H32O2
76119
Palmitic acid, analytical standard
C16H32O2
PHR1120
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
C16H32O2
P0090000
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
C16H32O2
P3350000
Proline, European Pharmacopoeia (EP) Reference Standard
C5H9NO2
S5922
Salicylic acid, BioXtra, ≥99.0%
C7H6O3
S7401
Salicylic acid, plant cell culture tested
C7H6O3
84210
Salicylic acid, puriss. p.a., ≥99.0% (T)
C7H6O3
27301
Salicylic acid, meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (calc. to the dried substance)
C7H6O3
1609002
Salicylic acid, United States Pharmacopeia (USP) Reference Standard
C7H6O3
84211
Salicylic acid, tested according to Ph.Eur.
C7H6O3
PHR1013
Salicylic acid, Pharmaceutical Secondary Standard; Certified Reference Material
C7H6O3
105910
Salicylic acid, ReagentPlus®, ≥99%
C7H6O3
W398500
Salicylic acid, ≥99%, FG
C7H6O3
52341
Salicylic acid, certified reference material, TraceCERT®
C7H6O3
S0200000
Salicylic acid, European Pharmacopoeia (EP) Reference Standard
C7H6O3